ArticleFrontiers in immunology2026

Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial.

Haiqi Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.